Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Summary of probe development efforts to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide
Assay data:11 Active, 1 Activity ≤ 1 µM, 20 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.
Assay data:2141 Active, 315100 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).
Assay data:2201 Active, 315100 Tested
Counterscreen for MCL1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of BCL2-related protein, long isoform (BCLXL).
Assay data:922 Active, 1720 Tested
Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.
Assay data:1050 Active, 1720 Tested
Fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.
Assay data:51 Active, 2 Activity ≤ 1 µM, 128 Tested
Counterscreen for inhibitors of MCL1: fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL).
Assay data:1 Active, 128 Tested
Late stage counterscreen results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL)
Assay data:20 Tested
Late stage counterscreen results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of BCL2-related protein, long isoform (BCLXL) (Probe)
Assay data:2 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: absorbance-based cell-based assay to identify compounds that are preferentially active in causing apoptosis in MCL-1 primed vs. Bax/Bak deficient DHL10 cells
Assay data:2 Active, 137 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture
Assay data:3 Active, 29 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based assay to identify compounds that preferentially activate caspase in 2B4/MCL-1 vs. 2B4/BCL-2 cells
Assay data:2 Activity ≤ 1 µM, 137 Tested
SummaryCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide
Assay data:6 Active, 115 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: absorbance-based cell-based assay to identify compounds that are preferentially active in causing apoptosis in Mcl-1 primed (2B4/Mcl1) vs. Bcl-2 (2B4/Bcl-2) cell lines
Assay data:8 Active, 8 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide, Round 3
Assay data:8 Active, 4 Activity ≤ 1 µM, 8 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: Fluorescence polarization-based biochemical dose response assay for inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide (Probe)
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Late stage assay provider results from the probe development effort to identify MCL1-BIM inhibitors: fluorescence-based cell-based cytotoxicity assay using 4',6-diamidino-2-phenylindole (DAPI) to identify compounds that are pro-apoptotic in cancer cells grown in culture (Probe)
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on